Lexaria Bioscience Corp. Reports Director and Officer Changes
Ticker: LEXX · Form: 8-K · Filed: Oct 2, 2024
Sentiment: neutral
Topics: management-change, compensation, board-of-directors
Related Tickers: LXRP
TL;DR
Lexaria Bioscience Corp. filed an 8-K detailing changes to its board and executive compensation effective Oct 1.
AI Summary
Lexaria Bioscience Corp. filed an 8-K on October 2, 2024, reporting changes related to its board of directors and officers, as well as compensatory arrangements. The filing indicates a shift in the company's leadership structure and potential adjustments to executive compensation, effective October 1, 2024.
Why It Matters
Changes in a company's board and executive team can signal strategic shifts or governance adjustments that may impact future operations and shareholder value.
Risk Assessment
Risk Level: medium — Changes in leadership and compensation can introduce uncertainty regarding future strategy and financial performance.
Key Players & Entities
- Lexaria Bioscience Corp. (company) — Registrant
- October 1, 2024 (date) — Effective date of reported changes
- October 2, 2024 (date) — Filing date of the 8-K
FAQ
What specific changes were made to the board of directors or officers?
The filing indicates changes related to the departure of directors or certain officers, election of directors, and appointment of certain officers, but the specific names and details are not provided in this excerpt.
What is the effective date of these reported changes?
The effective date for the changes reported in the 8-K is October 1, 2024.
What type of compensatory arrangements are being reported?
The filing mentions 'Compensatory Arrangements of Certain Officers,' suggesting adjustments or new agreements related to executive pay, but specific details are not in this excerpt.
What is the primary purpose of this 8-K filing?
This 8-K filing serves to report current information about significant corporate events, specifically changes in the company's directors and officers, and related compensatory arrangements.
Where is Lexaria Bioscience Corp. incorporated?
Lexaria Bioscience Corp. is incorporated in Nevada.
Filing Stats: 885 words · 4 min read · ~3 pages · Grade level 11.6 · Accepted 2024-10-02 12:21:50
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 per share Warrants to Purchase Common
- $120,000 — transaction with the Company exceeding $120,000. Mr. Shankman is a Certified Public A
- $160M — n worked for The Articom Group, being a $160M provider of refrigeration and HVAC desi
- $35M — man was the Controller for Change.Org a $35M public benefit corporation. In his pos
- $3 — ve an exercise price per share equal to $3.17, being one cent ($0.01) above the cl
- $0.01 — r share equal to $3.17, being one cent ($0.01) above the closing price of the Company
Filing Documents
- lxrp_8k.htm (8-K) — 26KB
- 0001640334-24-001473.txt ( ) — 164KB
- lxrp-20241001.xsd (EX-101.SCH) — 6KB
- lxrp-20241001_lab.xml (EX-101.LAB) — 16KB
- lxrp-20241001_cal.xml (EX-101.CAL) — 1KB
- lxrp-20241001_pre.xml (EX-101.PRE) — 12KB
- lxrp-20241001_def.xml (EX-101.DEF) — 4KB
- lxrp_8k_htm.xml (XML) — 5KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. LEXARIA BIOSCIENCE CORP. /s/ Richard Christopher Richard Christopher CEO, Principal Executive Officer Date: October 2, 2024 3